CRCT News
Role of sphingosin kinase 1 in cancer immunotherapy
Immunotherapy is a treatment that aims to educate our immune system against cancer cells. This treatment resulted in a long-term response in patients with metastatic melanoma (40-60%) with in some cases total tumour regression. The challenge is now that the maximum...
New therapeutic perspectives for dendrogenin A, a cholesterol-derived metabolite
Dendrogenin A (DDA) is a tumor suppressor mammalian cholesterol-derived metabolite and a new class of ligand of the Liver X receptor (LXR), which displays tumor cell differentiation. In human and mouse breast adenocarcinoma cells, DDA-induced cell differentiation was...
LungPredict: improve and personalize immuno-therapies
A collaboration in Toulouse, France, between Pierre Fabre Research Institute, the University Cancer Institute and the Cancer Research Center aims to collect and integrate data to improve and personalize immuno-therapies. Immunotherapies are imposing themselves as a...
Three major stakeholders of the Oncopole form a strategic public-private sector alliance to boost innovation in oncology on the Toulouse campus
A multi-year framework agreement has just been signed by 3 major stakeholders present on the Oncopole campus in Toulouse: the Pierre Fabre Research Institute (IRPF), the Centre de Recherches en Cancérologie de Toulouse (CRCT-Inserm) and the Institut Universitaire du...
Hervé Avet-Loiseau among the most influential researchers in 2019
Prof. Hervé Avet-Loiseau, head of the "Myeloma Genomics" unit at IUCT-Oncopole and the "Oncogenomics and immunology of myeloma" team at CRCT is on Clarivate Analytics' list of the most influential researchers of the past decade. This is a prestigious recognition of...
IMLINFO / Cross-border Network of Personalized Immunotherapies for Non-Hodgkin’s Lymphomas
IMLINFO is a cross-border network of personalized immunotherapies for Non-Hodgkin's lymphomas (NHL) involving 7 organizations located in Spain and France. Its main objective is to determine the efficacy of new immunotherapy treatments through the creation of a NHL...